ArticleSurgical endoscopy2026
Post-discharge VTE prophylaxis after bariatric surgery: balancing bleeding risk and thrombosis prevention in 275,843 patients.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-discharge venous thromboembolism (VTE) chemoprophylaxis after metabolic and bariatric surgery is variably implemented in clinical practice, although the optimal pharmacologic agent and dosing regimen remain unclear. This study characterized national practice patterns in VTE chemoprophylaxis and evaluated the associations of commonly prescribed post-discharge prophylactic regimens with VTE and bleeding outcomes.
methodsA retrospective analysis of a national database identified adult patients undergoing primary sleeve gastrectomy (n = 184,587) or Roux-en-Y gastric bypass (n = 91,256) between 2018 and 2025. The primary outcomes were VTE and bleeding events through 90 postoperative days (POD). Multivariable logistic regression and propensity score matching were used to evaluate the associations of common chemoprophylaxis regimens with VTE and bleeding.
resultsAmong 275,843 patients undergoing metabolic and bariatric surgery, 63,744 (23.1%) received post-discharge chemoprophylaxis. Overall post-discharge VTE incidence was 0.45% at POD30 and 0.61% at POD90. Enoxaparin 40 mg once daily was the most frequently prescribed regimen (35.8%; n = 22,799). On multivariable analysis, apixaban 2.5 mg twice daily (OR 0.62, 95% CI 0.41-0.90), rivaroxaban 10 mg once daily (OR 0.55, 95% CI 0.26-0.99), and enoxaparin 40 mg twice daily (OR 0.72, 95% CI 0.58-0.88) were independently associated with lower odds of VTE through POD90 without increased odds of bleeding compared with no prophylaxis. In propensity score-matched analyses, 90-day VTE incidence was lower for apixaban 2.5 mg twice daily (0.41% vs. 0.64%; p = 0.050; q = 0.050) and enoxaparin 40 mg twice daily (0.53% vs. 0.75%; p = 0.003) compared with matched controls.
conclusionsPost-discharge VTE chemoprophylaxis after metabolic and bariatric surgery varies substantially, with meaningful differences in safety and effectiveness across regimens. In propensity score-matched analyses, apixaban 2.5 mg twice daily and enoxaparin 40 mg twice daily were each associated with lower 90-day VTE incidence compared with matched controls, without significant increase in bleeding. Prospective randomized studies are needed to define optimal patient selection, regimen selection, and therapy duration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.